BenevolentAl Therapeutics Pipeline and Triage
BEN-8744: IBD Asset Overview
Best-in-class, oral, peripherally restricted potent and selective Phosphodiesterase 10 (PDE10)
inhibitor for the treatment of Moderate to Severe Ulcerative Colitis and Crohn's Disease (IBD)
Mechanism of Action
Formulation
Competitive Advantage
IP Position
Current Status
Asset Overview
Phosphodiesterase 10 (PDE10) inhibitor, immunomodulatory
Small molecule, oral, chronic treatment
New immunomodulatory mechanism of action, providing additional option to patients refractory to current
treatments
Disease modifying treatment targeting the disease mechanisms associated with IBD
Targeting induction and maintenance of clinical remission, allowing for reduction in long-term
corticosteroid use
Peripherally restricted, devoid of on-target central side effects
Clean safety profile compared to other oral small molecule competitors (e.g. JAK inhibitors,
tofacitinib/Xeljanz - black box warning for infection risk)
Precision Medicine approach for patient stratification
Second Medical Use & Composition of Matter patent applications filed
Commenced preclinical development, with Candidate selection completed August 2021
Benevolent 40
ΑΙView entire presentation